



aTyr Pharma

aTyr Pharma to Present at Two Upcoming Investor Conferences in March

March 1, 2018

SAN DIEGO, March 01, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced its participation at two investor conferences in March:

- A presentation at the Cowen and Company 38th Annual Health Care Conference in Boston on Monday, March 12, 2018 at 11:20 a.m. Eastern Time.
- A presentation at the Barclays Global Healthcare Conference in Miami on Thursday, March 15, 2018 at 2:05 p.m. Eastern Time.

Links to a live audio webcast and replay of the Cowen presentation may be accessed on the aTyr website events page at: <http://investors.atyrpharma.com/events-and-webcasts>. An audio replay will be available for 90 days following the event.

About aTyr Pharma

aTyr Pharma is engaged in the discovery and development of innovative medicines using its knowledge of newly discovered pathways in immunology effected by extracellular tRNA synthetases. To date, aTyr has generated innovative and unique development programs based on its knowledge of extracellular histidyl-tRNA synthetase (HARS), known as the Resokine pathway. aTyr's clinical stage ATYR1923 (iMod.Fc) program is an agonist of the Resokine pathway designed to temper immune engagement in interstitial lung diseases. aTyr's preclinical research stage ORCA program, targets a novel, proprietary immuno-oncology pathway using antibodies to enhance the immune response in tumor settings. aTyr has built an intellectual property estate, to protect its pipeline, comprising over 220 issued patents or allowed patent applications that are owned or exclusively licensed, including over 300 potential protein compositions derived from tRNA synthetase genes. For more information, please visit <http://www.atyrpharma.com>.

Contact:

Mark Johnson

Sr. Director, Investor Relations

mjohnson@atyrpharma.com

858-223-1163

 [Primary Logo](#)

Source: aTyr Pharma, Inc.